AMD eye drops trial kicks off

Article

TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).

TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).

TG100801 is administered non-invasively as an eye drop and has been developed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, oedema and angiogenesis.

A second topically applied compound for eye disease, TG100948, is also in early development.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
Related Content
The Eiffel Tower/La Tour Eiffel, as viewed from under a bridge in Paris, France. Concept image for EURETINA 25th anniversary and retina specialist meeting conference in Europe. Image credit: ©Dario – stock.adobe.com

What to expect at this year's European Society of Retina Specialists (EURETINA) Congress

Hattie Hayes
August 26th 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 26th 2025
Podcast
European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

Hattie Hayes
August 26th 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 26th 2025
Podcast
A mesh wire trash can with lots of wadded-up pieces of paper in it. Some of the pieces of paper have visible drawing. DNA helixes are drawn on some of the pieces of wadded-up paper. Concept image for gene therapy, age-related macular degeneration and new approach to AMD treatment. Image created with Canva AI Magic Media.

Starting from scratch on neovascular age-related macular degeneration

Lynda Charters
August 26th 2025
Article
A pharmacy in Montreal, Quebec, its "pharmacie" sign in French. Concept image for RAMQ approval of Vabysmo faricimab injection roche for macular oedema secondary to retinal vein occlusion. Image credit: ©Andriy Blokhin – stock.adobe.com

Québec announces faricimab (Vabysmo, Roche) will be funded for macular oedema secondary to RVO

Martin David Harp
August 26th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.